NASDAQ:VINC Vincerx Pharma (VINC) Stock Price, News & Analysis $0.01 0.00 (0.00%) As of 06/11/2026 01:06 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About Vincerx Pharma Stock (NASDAQ:VINC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vincerx Pharma alerts:Sign Up Key Stats Today's Range$0.0131▼$0.013150-Day Range$0.0122▼$0.017052-Week Range$0.00▼$0.07Volume437 shsAverage Volume4,799 shsMarket Capitalization$68.57 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vincerx Pharma, Inc., headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for patients with hematologic malignancies and other oncology indications. The company’s research platform centers on selective kinase inhibition and biomarker-driven approaches, with the goal of addressing high unmet medical needs in blood cancers that have limited treatment options. Vincerx’s lead product candidate, pacritinib—an oral JAK2/IRAK1 inhibitor—was in-licensed from CTI BioPharma Corp. and is being evaluated for the treatment of myelofibrosis, particularly in patients with severe thrombocytopenia and other challenging clinical profiles. The company is advancing pacritinib through pivotal clinical trials to assess its safety and efficacy as both monotherapy and in combination with other targeted agents. In parallel, Vincerx is progressing next-generation compounds designed to modulate additional signaling pathways implicated in hematologic and solid tumor biology. The company’s management team brings extensive experience in oncology drug development, clinical operations and regulatory strategy. Vincerx collaborates with leading academic institutions and clinical research sites across North America and Europe to execute its global trial program. This collaborative framework, combined with a patient-centric trial design philosophy, underscores Vincerx’s commitment to delivering innovative cancer therapies to the medical community.AI Generated. May Contain Errors. Read More Receive VINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VINC Stock News HeadlinesAntibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 DrugsApril 14, 2026 | finance.yahoo.comVincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...July 16, 2025 | gurufocus.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free. | Behind the Markets (Ad)Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution ProposalJuly 16, 2025 | globenewswire.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - MorningstarJuly 9, 2025 | morningstar.comMVincerx Pharma, Inc. Common Stock (VINC) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to StockholdersJuly 7, 2025 | globenewswire.comVincerx Pharma, Inc. (VINC) - Yahoo FinanceJuly 2, 2025 | ca.finance.yahoo.comSee More Headlines VINC Stock Analysis - Frequently Asked Questions How have VINC shares performed this year? Vincerx Pharma's stock was trading at $0.0126 at the start of the year. Since then, VINC stock has increased by 4.0% and is now trading at $0.0131. How were Vincerx Pharma's earnings last quarter? Vincerx Pharma, Inc. (NASDAQ:VINC) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($1.00) EPS for the quarter, topping the consensus estimate of ($3.40) by $2.40. When did Vincerx Pharma's stock split? Shares of Vincerx Pharma reverse split on Tuesday, January 28th 2025.The 1-20 reverse split was announced on Thursday, January 23rd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Vincerx Pharma? Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vincerx Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vincerx Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and Company Calendar Last Earnings8/08/2024Today6/11/2026Next Earnings (Estimated)8/07/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VINC CIK1796129 Webvincerapharma.com Phone650-800-6676FaxN/AEmployees60Year FoundedN/AProfitability EPS (Trailing Twelve Months)($5.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$40.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-248.33% Return on Assets-132.73% Debt Debt-to-Equity RatioN/A Current Ratio2.17 Quick Ratio2.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.50 per share Price / Book0.00Miscellaneous Outstanding Shares5,234,000Free Float1,891,000Market Cap$68.57 thousand OptionableNot Optionable Beta1.46 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:VINC) was last updated on 6/12/2026 by MarketBeat.com Staff. From Our PartnersIs your wealth prepared for “America’s Most Dangerous Man”? (Read before June 16)60-year Wall Street veteran Marc Chaikin is issuing an urgent warning about the billionaire behind an AI lab t...Chaikin Analytics | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredLive demo of Elon Musk’s AI agentJeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThis Is How Financial Freedom Dies—And Most People Never See It ComingWhile the trade war grabs headlines, the Department of Justice has quietly argued in court that cash may not b...Priority Gold | SponsoredJon Najarian: “Make this move now that SPCX is trading”SpaceX is now publicly trading under the ticker SPCX - but Hall of Fame Trader Jon Najarian says the real oppo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vincerx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VINC Stock Alerts